ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO046

Impact of Statins on Mortality and Length of Hospital Stay among Patients with AKI: A Systematic Review and Meta-Analysis

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Alshareef, Abdulmueti, Zawia Teaching Hospital, Zawia, Libya
  • Abudrea, Mutaz Bellah, Tripoli Medical Center, Tripoli, Tripoli, Libya
  • Elkhadar, Abdulmohimen Adel M, Tripoli Medical Center, Tripoli, Libya
  • Ben Shady, Ibrahim, Tripoli Medical Center, Tripoli, Libya
Background

Acute kidney injury (AKI) is a frequent complication in critically ill patients, with very high mortality rates. Several studies have suggested that statin therapy, beyond its effects on cholesterol, may have impacts on the course of AKI and its complications. However, we conduct a systematic review and meta-analysis to assess the impact of statin on mortality and the length of hospital stay in hospitalized AKI patients

Methods

We conducted a systematic review and meta-analysis to investigate the impact of Statin on the Length of hospital stay in AKI patients, A literature search was performed using electronic databases and engines including; PubMed, Google Scholar, Scopus, and Web of Science, from inception to May 2024. We included all Original studies that investigate the mortality and length of hospital stay among hospitalized AKI patients.

Results

Nine studies were included in our meta-analysis, the pooled analysis showed a statistically significant reduction in the length of hospital stay for patients using statins compared to those not using statins. The overall standardized mean difference (SMD) was -0.21 (95% CI: -0.32, -0.08), indicating a moderate effect size favoring statin use. In terms of mortality, the pooled analysis of three studies showed a significant reduction of mortality with statin therapy OR (95% CI), 0.728 (0.68, 0.77) (p < 0.001)

Conclusion

Our current meta-analysis shows that important beneficial association between statin use and reduction of the overall mortality and reduction of hospital stay length among hospitalized AKI patients, Highlighting the potential benefits of statins beyond their lipid-lowering effects.
Even with a limited number of studies that investigate the association, these findings should be further explored in ongoing international, randomized clinical trials.